Autores: Ridruejo Ezequiel, Solano Ángela, Marciano Sebastián, Galdame Omar, Adrover Raúl, Cocozzella Daniel, Delettieres Dreanina, et al
Background and aims: Genetic variations in the interleukin 28B (IL28B) gene have been associated with viral response to PEG-interferon-„´/ribavirin (PR) therapy in hepatitis C virus (HCV) genotype 1 infected patients from North America, Europe and Asia. The importance of these IL28B variants for Argentine patients remains unknown. Material and methods: IL28B host genotypes (rs8099917 and rs12979860) were determined in a population of Argentine patients with European ancestry. Results were analyzed looking for their association with sustained virologic response (SVR) to PR therapy and compared with other baseline hosts¡¦ biochemical, histological and virological predictors of response. Results: We studied 102 patients, 60% were men, and 40% of them were rs8099917 TT and 18% rs12979860 CC. Mean baseline serum HCV RNA was 1.673.092 IU/mL and mean F score was: 2.10 ¡Ó 1.18 (21% cirrhotic). SVR rate was higher in rs8099917 TT genotypes (55%) when compared to GT/GG (25%) (p = 0.002) and in rs1512979860 CC (64%) than in CT/TT (30%) (p = 0.004). The univariate analysis showed that rs8099917 TT (OR 3.7; 95 %CI 1.5-8.7; p = 0.002), rs12979860 CC (OR 4.6; 95%CI 1.5-13.7; p = 0.006), low viral load (OR 4.6; 95% CI 1.7-12.6; p = 0.002) and F0-2 (OR 8.5; 95% CI 2.3-30.6; p = 0.001) were significantly associated with SVR. In the multivariate analysis, rs12979860 CC, rs8099917 TT, viral load < 400.000 IU/mL and F0-2 were associated with SVR rates (p = 0.029, p = 0.012, p = 0.013 and p = 0.004, respectively). Conclusion: IL28B host genotypes should be added to baseline predictors of response to PR therapy in Latin American patients with European ancestry.
Palabras clave: Hepatitis C sustained virological response IL28B single-nucleotide polymorphisms european ancestry Latin american patients.
2011-09-13 | 673 visitas | Evalua este artículo 0 valoraciones
Vol. 10 Núm.4. Octubre-Diciembre 2011 Pags. 452-457 Ann Hepatol 2011; 10(4)